Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis

被引:5
|
作者
Holz, Frank G. [1 ]
Tadayoni, Ramin [3 ]
Beatty, Stephen [4 ]
Berger, Alan R. [5 ,6 ]
Cereda, Matteo G. [7 ]
Hykin, Philip [8 ]
Hoyng, Carel B. [10 ]
Wittrup-Jensen, Kim [2 ]
Altemark, Andreas [2 ]
Nilsson, Jonas [11 ]
Kim, Kun [12 ]
Sivaprasad, Sobha [8 ,9 ]
机构
[1] Univ Bonn, Dept Ophthalmol, Bonn, Germany
[2] Bayer Pharmaceut, Berlin, Germany
[3] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France
[4] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland
[5] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[6] St Michaels Hosp, Toronto, ON, Canada
[7] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy
[8] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England
[9] Kings Coll Hosp London, Dept Ophthalmol, London, England
[10] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands
[11] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden
[12] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden
关键词
AURA; Intravitreal ranibizumab; Neovascular age-related macular degeneration; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; LIFE; AMD;
D O I
10.1159/000449001
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA. Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA). Results: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success. Conclusion: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:49 / 55
页数:7
相关论文
共 50 条
  • [1] Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
    Finger, Robert P.
    Wickremasinghe, Sanjeewa S.
    Baird, Paul N.
    Guymer, Robyn H.
    SURVEY OF OPHTHALMOLOGY, 2014, 59 (01) : 1 - 18
  • [2] Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration
    Borrelli, Enrico
    Foti, Claudio
    Ulla, Lorena
    Porreca, Annamaria
    Introini, Ugo
    Grassi, Maria Oliva
    Viggiano, Pasquale
    Peronetti, Mario
    Toscani, Rebecca
    Boscia, Giacomo
    Termite, Alba Chiara
    Gennaro, Carlo
    Marolo, Paola
    Boscia, Francesco
    Bandello, Francesco
    Reibaldi, Michele
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2025,
  • [3] Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
    Wykoff, Charles C.
    Clark, W. Lloyd
    Nielsen, Jared S.
    Brill, Joel V.
    Greene, Laurence S.
    Heggen, Cherilyn L.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (02) : S3 - S15
  • [4] Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
    Pfau, Maximilian
    Sahu, Soumya
    Rupnow, Rawan Allozi
    Romond, Kathleen
    Millet, Desiree
    Holz, Frank G.
    Schmitz-Valckenberg, Steffen
    Fleckenstein, Monika
    Lim, Jennifer, I
    de Sisternes, Luis
    Leng, Theodore
    Rubin, Daniel L.
    Hallak, Joelle A.
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2021, 10 (07):
  • [5] Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration
    Fauser, Sascha
    Lambrou, George N.
    SURVEY OF OPHTHALMOLOGY, 2015, 60 (02) : 138 - 152
  • [6] Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration
    Kim, Bo Hee
    Chang, In Boem
    Yu, Hyeong Gon
    Hong, In Hwan
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2023, 16 (06) : 909 - 914
  • [7] Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
    Strunz, Tobias
    Poellmann, Michael
    Gamulescu, Maria-Andreea
    Tamm, Svenja
    Weber, Bernhard H. F.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (11)
  • [8] Real-world evidence of anti-VEGF therapies in patients with neovascular age-related macular degeneration in Italy: The RADIANCE study
    Parravano, Mariacristina
    Viola, Francesco
    Nicolo, Massimo
    Vujosevic, Stela
    Bianchino, Laura
    Sicari, Emilia
    Villa, Giulia
    Lanzetta, Paolo
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2025,
  • [9] Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update
    Parravano, Mariacristina
    Costanzo, Eliana
    Scondotto, Giulia
    Trifiro, Gianluca
    Virgili, Gianni
    BIODRUGS, 2021, 35 (06) : 673 - 692
  • [10] Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials
    Yamashiro, Kenji
    Oishi, Akio
    Hata, Masayuki
    Takahashi, Ayako
    Tsujikawa, Akitaka
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2021, 65 (06) : 741 - 760